Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis

Multiple Sclerosis : Clinical and Laboratory Research
Aaron MillerRivka Riven Kreitman

Abstract

To evaluate the safety and efficacy of long-term glatiramer acetate (GA) therapy, 46 patients with relapsing-remitting multiple sclerosis (RRMS) were treated for up to 22 years in an ongoing, open-label study. Kurtzke expanded disability status scale (EDSS) was measured every six months, relapses were reported at occurrence and patients self-reported adverse events (AEs). At GA initiation, disease durations ranged from 0-20 years (median 6.0 years) and at data cut-off (October 2004), GA therapy duration ranged from 1-22 years (median 12.0 years). Mean EDSS score increased 0.9 +/- 1.9 from the pretreatment score (3.0 +/- 1.8; P = 0.076). Only 10/28 (36%) patients with baseline EDSS <4.0 had a last observed value >or= 4.0 and 8/34 (24%) with entry EDSS < 6.0 reached EDSS >or= 6.0. A majority (57%) maintained improved or unchanged EDSS scores. Annualized relapse rate decreased to 0.1 +/- 0.2 from 2.9 +/- 1.4 prestudy (P < 0.0001). Of the 18 remaining patients in October 2004 (average disease duration 23 years), 17% with baseline EDSS scores < 4.0 reached EDSS >or= 4.0 and 28% with baseline scores < 6.0 reached EDSS >or= 6.0. Adverse events were similar to those reported in short-term clinical trials. This study shows a low rate of...Continue Reading

References

Aug 13, 1987·The New England Journal of Medicine·M B BornsteinV Spada
Jan 1, 1984·Annals of the New York Academy of Sciences·M B BornsteinD Teitelbaum
Mar 1, 1982·Annals of Neurology·M B BornsteinM Sela
Jul 17, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·S A Hawkins, G V McDonnell
Nov 18, 2000·The New England Journal of Medicine·C ConfavreuxP Adeleine
Nov 13, 2002·Neurology·E FisherN A Simonian
Aug 5, 2004·Annals of Neurology·Sean J PittockMoses Rodriguez
Jan 26, 2006·Neurology·Helen TremlettVirginia Devonshire
Mar 3, 2006·The New England Journal of Medicine·Tarek A YousryDavid B Clifford
Jun 13, 2006·Multiple Sclerosis : Clinical and Laboratory Research·C C FordUNKNOWN Copaxone Study Group
Dec 4, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·G Ebers

❮ Previous
Next ❯

Citations

Mar 28, 2009·Journal of Neurology·Bernd C KieseierOlaf Stüve
Feb 21, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Dimitrios Karussis
Nov 19, 2011·Multiple Sclerosis International·Mona Alkhawajah, Joel Oger
Sep 27, 2014·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Carmen Arnal-GarcíaUNKNOWN XPERIENCIA-5 Study Group
Oct 10, 2009·Current Opinion in Ophthalmology·John H Pula, Adil Javed
Jan 8, 2013·European Journal of Medicinal Chemistry·Naveen MulakayalaSrinivas Oruganti
Mar 29, 2011·Neurologic Clinics·Maria TrojanoMariangela D'Onghia
Feb 10, 2009·Journal of the Neurological Sciences·Thibault Moreau
Sep 9, 2008·Drug Discovery Today·Georg PilzJörg Kraus
Mar 1, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Deepak M W BalakH Bing Thio
Oct 20, 2011·Therapeutic Advances in Neurological Disorders·Aaron BosterMichael Racke
Jun 1, 2009·Acta Neuropsychiatrica·Sven G MeuthHeinz Wiendl
Aug 24, 2010·Arquivos de neuro-psiquiatria·Lineu Cesar WerneckRosana Herminia Scola
Jan 1, 2012·Journal of Central Nervous System Disease·Oscar Fernández
Dec 1, 2012·Therapeutic Advances in Drug Safety·Daniel Ontaneda, Daniela Di Capua
Feb 15, 2018·Cold Spring Harbor Perspectives in Medicine·Thomas Prod'homme, Scott S Zamvil
May 14, 2010·The Cochrane Database of Systematic Reviews·Loredana La MantiaRoberta Lovati
Oct 1, 2010·Continuum : Lifelong Learning in Neurology·Amer M Awad, Olaf Stüve
Jun 6, 2009·Experimental Biology and Medicine·Erez KorenIsaac Ginsburg
Mar 24, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Alison LindsayMythily Srinivasan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.